Konica Minolta’s Medical Units Race to Develop Tests and Drugs to Halt Coronavirus


Nearly three years ago, Konica Minolta acquired two U.S.-based medical companies, genetics testing company Ambry Genetics Corporation (see “Konica Minolta to Buy U.S.-Based Ambry Genetics for $1 Billion”) and Invicro LLC, a contract research organization (CRO) that uses imaging technology and data analytics for drug development (see “Konica Minolta Strengthens Healthcare Position with Invicro Acquisition”).

To see the rest of this post, please view membership options or log in to your account below.


error: Alert: Content is protected !!